Fraunhofer Institute For Translational Medicine And Pharmacology ITMP

4 trials 3 recruiting Academic / non-commercial

Filter these 4 trials by condition, phase, country and more.

Open in Search →
4 Registered trials
3 Recruiting
1 Completed trials
1 Countries active
6 Unique IMPs
100% Results reported
Phase II: 2 Phase I/II: 2
100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Attention deficit hyperactivity disorder 1 Rheumatoid arthritis 1 Major depression 1 Idiopathic inflammatory myopathy 1 Chronic spontaneous urticaria 1

Top IMPs

CIZUTAMIG 1 CND261 1 DEXAMFETAMINE SULFATE 1 NEISSERIA MENINGITIDIS, SEROGROUP C, POLYSACCHARIDE, CONJUGATED TO TETANUS TOXOID, NEISSERIA MENINGITIDIS GROUP A POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN, NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN, NEISSERIA MENINGITIDIS GROUP Y POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN 1 RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, OUTER MEMBRANE VESICLES (OMV) FROM NEISSERIA MENINGITIDIS GROUP B STRAIN NZ98/254 MEASURED AS AMOUNT OF TOTAL PROTEIN CONTAINING THE PORA P1.4 ADSORBED ON ALUMINIUM HYDROXIDE 1

All trials

4 total

Showing 1–4 of 4 trials

← All sponsors A–Z